Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 501–600 of 736
Sensitive Measures of Cognition in Mild Cognitive Impairment
Klooster, N. B., Humphries, S. A., Cardillo, E. R., Hartung, F., Xie, L., Das, S. R., Yushkevich, P. A., Pilania, A., Wang, J., Wolk, D. A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201280 · Cited by 11
“As the presence and location of neurofibrillary tangles often mirror the pattern of neurodegeneration and resulting cognitive decline [70-71], we predict that semantic task performances will be especially sensitive to the presence of Tau.”
Ni, W., Jagust, W. J., & Wang, D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00424 · Cited by 10
Stracke, S., Lange, S., Bornmann, S., Kock, H., Schulze, L. N., Klinger-König, J., Böhm, S., Vogelgesang, A., von Podewils, F., Flöel, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061919 · Cited by 9
Strategies for measuring concentrations and forms of amyloid-β peptides
Shen, H., Liu, K., Kong, F., Ren, M., Wang, X., & Wang, S. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116405 · Cited by 10
Anderson, J. A. E., Schifani, C., Nazeri, A., Voineskos, A. N., & Initiative, A. D. N. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70167 · Cited by 13
Overview of Proteomic Analysis of Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease
Grewal, A., Raikundalia, S., Zaia, J., & Sethi, M. K. (2025) · Biomolecules · doi:10.3390/biom15091310 · Cited by 10
“The tau protein is a central driver of neurodegeneration in AD, with its accumulation in the form of NFTs strongly correlating with disease progression and cognitive decline [27,28].”
Chong, C., Tan, Y., Tong, J., Ke, M., Zhang, K., Yan, L., Cen, X., Lu, J., Chen, G., Su, H., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00874-8 · Cited by 11
Li, J., Xu, S., Wang, L., & Wang, X. (2023) · Pharmaceuticals · doi:10.3390/ph16020305 · Cited by 9
Kim, C. M., Diez, I. P., Bueichekú, E., Ahn, S., Montal, V., & Sepulcre, J. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0488-23.2023 · Cited by 8
CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors
Pappas, C. A., Klinedinst, B. S., Le, S. T., Wang, Q., Larsen, B. A., McLimans, K. E., Lockhart, S. N., Allenspach‐Jorn, K., Mochel, J. P., Willette, A. A., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12080 · Cited by 7
Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient
Day, G. S., Gordon, B. A., Bucelli, R. C., Perrin, R. J., Lopez-Chiriboga, A. S., & Ances, B. M. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577474 · Cited by 8
Self-citationAssessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease
Keleman, A. A., Bollinger, R. M., Wisch, J. K., Grant, E., Benzinger, T. L. S., Ances, B. M., & Stark, S. L. (2022) · OTJR Occupational Therapy Journal of Research · doi:10.1177/15394492221100701 · Cited by 11
“Rs-fc preprocessing methods have been documented elsewhere (Brier et al., 2012, 2016; Thomas et al., 2014).”
MethodSelf-citationAging-associated REGγ proteasome decline predisposes to tauopathy
Tu, J., Zhang, H., Yang, T., Liu, Y., Kibreab, S., Zhang, Y., Gao, L., Moses, R. E., O’Malley, B. W., Xiao, J., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102571 · Cited by 10
“Recent studies indicated that tau, not Aβ, may be the key etiological factor for the symptoms of AD (10) and that tau deposits are a biomarker for monitoring AD (11), as well as tauopathies.”
BackgroundPetersen, K. K., Ezzati, A., Lipton, R. B., Gordon, B. A., Hassenstab, J. J., Morris, J. C., & Grober, E. H. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.98 · Cited by 8
Self-citationTau and Pet/Mri Imaging Biomarkers for Detecting and Diagnosing Early Dementia.
Zhou, Y., & Bai, B. (2017) · PubMed · Cited by 9
Adji, A. S., Widjaja, J. S., Wardani, V. A. K., Muhammad, A. H., Handajani, F., Putra, H. B. P., & Rahman, F. S. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9053 · Cited by 9
Optimizing Medical Imaging Quality: An In-Depth Examination of Preprocessing Methods for Brain MRIs
Viswan, V., Shaffi, N., Karthikeyan, S., & Hajamohideen, F. (2024) · Communications in computer and information science · doi:10.1007/978-3-031-68639-9_5 · Cited by 10
Ao, J., Picard, C., Auld, D. S., Zetterberg, H., Brinkmalm, A., Blennow, K., Villeneuve, S., Breitner, J. C. S., Poirier, J., Breitner, J., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-024-02884-z · Cited by 12
“Because synaptic dysfunction, degeneration, and loss correlate strongly with cognitive decline in AD [6 – 8], measurable markers of synaptic pathology are of potential interest for this purpose, along with better-known indicators of amyloid and, especially, tau pathology [9, 10].”
Régy, M., Dugravot, A., Sabia, S., Bouaziz-Amar, É., Paquet, C., Hanseeuw, B. J., Singh‐Manoux, A., & Dumurgier, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01220-x · Cited by 7
Boz, H. E., Koçoğlu, K., Akkoyun, M., Tüfekçi, I. Y., Ekin, M., & Akdal, G. (2023) · Brain and Behavior · doi:10.1002/brb3.3232 · Cited by 9
“High levels of CSF phosphorylated tau (P-tau) have been identified as biomarkers of fibril tau (Brier et al., 2016; Chhatwal et al., 2016; Mattsson et al., 2009).”
BackgroundBransby, L., Yassi, N., Rosenich, E., Buckley, R. F., Li, Q., Maruff, P. T., Pase, M. P., & Lim, Y. Y. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.02.015 · Cited by 7
“While the relationship between tau and cognition has been demonstrated consistently in this sample and others (Brier et al., 2016; Lim et al., 2023), this may suggest that the relationship between multido-main MDRFs and poorer cognition in middle-aged and older adults reflects involvement of other…”
ResultLiu, S., Luo, X., Chong, J. S. X., Jiaerken, Y., Youn, S. H., Zhang, M., Zhou, J. H., & Initiative, A. D. N. (2024) · Human Brain Mapping · doi:10.1002/hbm.26765 · Cited by 8
“In support of this, tau has been demonstrated to be more closely related to cognitive decline than amyloid burden (Brier et al., 2016; Hanseeuw et al., 2019; Ossenkoppele et al., 2022; Strikwerda-Brown et al., 2022).”
BackgroundThe role of the gut microbiome in the regulation of astrocytes in Alzheimer's disease
Chandra, S., & Vassar, R. J. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00425 · Cited by 7
Xu, Z., Lu, W. D., Miao, Y., Li, H., Xie, X., & Zhang, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106792 · Cited by 10
Kim, Y., & Cho, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105071 · Cited by 8
Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition
Weigand, A. J., Initiative, A. D. N., Macomber, A. J., Walker, K. S., Edwards, L., Thomas, K. R., Bangen, K. J., Nation, D. A., & Bondi, M. W. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220026 · Cited by 8
Ghazimoradi, M. M., Pour, M. G., Ghoushi, E., Ahmadabadi, H. K., & Rafieian‐Kopaei, M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230222093016 · Cited by 7
Zhang, Z.-X., Zhao, R., Wang, D., & Li, Y.-B. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2028-4 · Cited by 8
Soares, J. Z., Valeur, J., Benth, J. Š., Knapskog, A., Selbæk, G., Bogdanović, N., & Pettersen, R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220407 · Cited by 8
Cortical Tau Aggregation Patterns Associated With Apraxia in Patients With Alzheimer Disease
Bischof, G. N., Jaeger, E., Giehl, K., Jessen, F., Onur, O. A., O’Bryant, S. E., Kara, E., Weiss, P. H., & Drzezga, A. E. (2024) · Neurology · doi:10.1212/wnl.0000000000210062 · Cited by 8
David, J., Quenon, L., Hanseeuw, B. J., Ivanoiu, A., Volfart, A., Koessler, L., & Rossion, B. (2024) · Clinical Neurophysiology · doi:10.1016/j.clinph.2024.12.018 · Cited by 8
Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease
Li, X., Li, Z., Chen, H., Guo, H., Ge, Y., Dong, F., Zhang, F., & Zhang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115199 · Cited by 8
Role of Human Serum Albumin in the Prevention and Treatment of Alzheimer’s Disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2024) · Biology Bulletin Reviews · doi:10.1134/s2079086424010109 · Cited by 9
“Data on the presence of a correlation between the accumulation of neurofibrillary tangles and the severity of dementia (Brier et al., 2016) made tau protein an important target for the development of approaches to the treatment of AD.”
Barber, P., Schaeffer, M. J., & Chan, L. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303011 · Cited by 6
“Summary and limitations Despite being a relatively new modality, preliminary evidence suggests that tau PET may be a good candidate biomarker for assessing and predicting cognitive decline in demented and non-demented adults, perhaps even outperforming amyloid PET (Brier et al., 2016; Aschenbrenner et al., 2018).”
BackgroundCSF phosphorylated tau as an indicator of subsequent tau accumulation
Cogswell, P. M., Wiste, H. J., Mielke, M. M., Schwarz, C. G., Weigand, S. D., Lowe, V. J., Therneau, T. M., Knopman, D. S., Graff‐Radford, J., Vemuri, P., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.02.015 · Cited by 8
Regional times to equilibria and their impact on semi-quantification of [ 18 F]AV-1451 uptake
Heurling, K., Smith, R. A., Strandberg, O. T., Schain, M., Ohlsson, T. G., Hansson, O., & Schöll, M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18791430 · Cited by 8
Screening for Core Genes Related to Pathogenesis of Alzheimer’s Disease
Yang, L.-X., Qin, Y. H., & Jian, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668738 · Cited by 9
“Neurofibrillary tangles are another pathological feature of AD patients, besides, phosphorylated tau aggregates proteins to cause neuron damage, and drugs targeting tau are promising for AD therapy (Brier et al., 2016; Gauthier et al., 2016; Li and Gotz, 2017; Novak et al., 2017).”
BackgroundHome cage measures of Alzheimer's disease in the rTg4510 mouse model
Barabas, A. J., Robbins, L., & Gaskill, B. N. (2022) · Genes Brain & Behavior · doi:10.1111/gbb.12795 · Cited by 5
Optical signature of retinal Tau fibrillation
Salajková, Z., Barolo, L., Baiocco, P., Ruzicka, B., Mura, F., Lorenzo, F. D., Boffi, A., Ricco, V., Ruocco, G., & Leonetti, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-92565-w · Cited by 5
Weiner, S., Sauer, M., Montoliu‐Gaya, L., Benedet, A. L., Ashton, N. J., González‐Ortiz, F., Simrén, J., Rahmouni, N., Tissot, C., Therriault, J., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00841-0 · Cited by 10
“Although Aβ plaque formation precedes tau pathology, it has been shown that NFT load is, in fact, more closely linked to cognition and disease progression [6].”
Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers
Harput, E., Boccalini, C., Mathoux, G., Prior, J. O., Dardel, N. T., Jreige, M., & Garibotto, V. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70163 · Cited by 6
Cui, X., Li, M., Lei, G., Wang, J., Pan, J., Zhu, S., Wu, T., Zou, L., & Yan, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1453051 · Cited by 5
Fließbach, K., & Schneider, A. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0488-2 · Cited by 8
Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer’s disease
Paranjpe, M. D., Chaffin, M. D., Zahid, S., Ritchie, S. C., Rotter, J. I., Rich, S. S., Gerszten, R. E., Guo, X., Heckbert, S. R., Tracy, R., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010294 · Cited by 5
Wu, J., Initiative, A. D. N., Su, Y., Zhu, W., Mallak, N. J., Leporé, N., Reiman, E. M., Caselli, R. J., Thompson, P. M., Chen, K., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220812 · Cited by 6
Self-citationSimon, S. S., Varangis, E. M. L., Lee, S., Gu, Y., Gazes, Y., Razlighi, Q. R., Habeck, C. G., & Stern, Y. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.10.001 · Cited by 7
Mohaupt, P., Vialaret, J., Hirtz, C., & Lehmann, S. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12456 · Cited by 6
Viswan, V., Hajamohideen, F., Subramanian, K., Shaffi, N., & Mahmud, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22158-3.00006-5 · Cited by 6
Emmerson, J. T., Carmo, S. D., Lavagna, A., Huang, C., Wong, T. P., Martínez-Trujillo, J., & Cuello, A. C. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01901-0 · Cited by 5
The Amyloid Precursor Protein: More than Just Amyloid- Beta
Jevtic, S. D., & Provias, J. (2019) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2019-045 · Cited by 6
“While Aβ plaque formation is one of the hallmarks of AD neuropathology, it has recently been confirmed that cognitive decline clinically correlates with onset of tau pathology as shown by PET scanning [81-86].”
BackgroundHuang, Y.-Y., Chiu, M., Yen, R., Tsai, C.-L., Hsieh, H.-Y., Chiu, C., Wu, C., Hsin, L., Tzen, K., Cheng, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217384 · Cited by 5
Validity and Normative Data for the Biber Figure Learning Test: A Visual Supraspan Memory Measure
Gifford, K. A., Liu, D., Neal, J. E., Acosta, L. M. Y., Bell, S. P., Wiggins, M. E., Wisniewski, K. M., Godfrey, M., Logan, L. A., Hohman, T. J., et al. (2018) · Assessment · doi:10.1177/1073191118773870 · Cited by 5
“Additionally, tau correlates with objective cognitive performance (Samgard et al., 2010), including episodic memory (Fjell et al., 2008), often more closely than markers of amyloidosis (Brier et al., 2016).”
BackgroundSimultaneous Covariance Inference for Multimodal Integrative Analysis
Yin, X., Li, L., Lockhart, S. N., & Jagust, W. J. (2019) · Journal of the American Statistical Association · doi:10.1080/01621459.2019.1623040 · Cited by 8
“Studies combining such tracers suggest that globally increasing Aβ burden is associated with greater neocortical accumulation of tau (Brier et al. 2016; Lockhart et al. 2017).”
BackgroundClinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
Franceschi, A. M., Keir, G., Benzinger, T. L. S., Cogswell, P. M., Ali, F., Petrella, J. R., Prescott, J. W., Whitlow, C. T., Zaharchuk, G., Allen, J. W., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8738 · Cited by 6
Self-citationTri-snRNP activity modulates tauopathy phenotypes
LeBlanc, K. R., Eck, R. J., Saxton, A. D., McMillan, P. J., Wheeler, J. M., Liachko, N. F., Keene, C. D., Latimer, C. S., Kow, R. L., & Kraemer, B. C. (2025) · NAR Molecular Medicine · doi:10.1093/narmme/ugaf032 · Cited by 5
Dan, T., Ding, J., & Guorong Wu, A. (2025) · Nature Communications · doi:10.1038/s41467-025-64471-2 · Cited by 5
“2, our Holo-Brain reproduces quite similar interference patterns along the off-diagonal lines, while revealing more pronounced group differences.”
Riku, Y., Brion, J., Ando, K., Uchihara, T., & Iwasaki, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412088 · Cited by 6
Zou, Y., Sang, Y., Zheng, M., & Shi, B. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102685 · Cited by 8
Rao, I. Y., Hanson, L. R., & Frey, W. H. (2025) · Pharmaceuticals · doi:10.3390/ph18020271 · Cited by 5
“The neurofibrillary tangles that form with accumulation of p-tau have shown a stronger correlation with memory loss and disease progression than amyloid beta plaques and disease-modifying therapies for this hypothesis are being developed [5].”
Ni, C., & Hutchins, B. I. (2025) · Journal of the Association for Information Science and Technology · doi:10.1002/asi.25009 · Cited by 7
“Competing hypotheses posit the involvement of the protein Tau as the primary driver of AD (Brier et al., 2016).”
Nanopathways modulating postoperative cognitive dysfunction: extracellular vesicles
Zhang, Y., Yin, Z., Zou, Z., Feng, S., & Xu, H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1613378 · Cited by 4
Chockanathan, U., & Padmanabhan, K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15636 · Cited by 7
Khaled, M., Al-Jamal, H., Tajer, L., & El-Mir, R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231432 · Cited by 4
Olcay, B. O., Pehlivan, M., & Karaçalı, B. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107566 · Cited by 4
Wan, Z., & Ma, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0303486 · Cited by 4
Xiong, C., Lu, R., Bui, Q. V. P., Popp, B., Schindler, S. E., Shriver, L. P., Cruchaga, C., Hassenstab, J. J., Benzinger, T. L. S., Agboola, F., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251362667 · Cited by 5
Self-citationJang, J., & Kim, S. (2019) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2019.1.1 · Cited by 4
“즉, 생물표지자 분류를 크게 3개 의 범주로 나누었는데, ‘A (=Amyloidopathy)’는 베타아밀로이드 관련 지표로 뇌피질의 amyloid-PET 리간드의 결합이나 뇌척수액 에서의 Aβ42 (또는 Aβ42/Aβ40)의 감소로 정의하였고,(14,15) ‘T (=Tauopathy)’는 신경원섬유매듭 형태의 타우 관련 지표로 뇌척수 액에서의 인산화 타우의 증가나 뇌피질의 tau-PET 리간드의 결합 으로 정의하였다.(16,17) ‘(N) (=Neurodegeneration or Neuronal injury)’은 신경퇴행의 지표로 뇌척수액 총 타우의 증가 또는 MR…”
Nuño, M. M., Grill, J. D., Gillen, D. L., & Initiative, A. D. N. (2021) · Clinical Trials · doi:10.1177/17407745211034497 · Cited by 4
Gicas, K. M., Honer, W. G., Petyuk, V., Wilson, R. S., Boyle, P. A., Leurgans, S. E., Schneider, J. A., Jager, P. L. D., & Bennett, D. A. (2023) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2023.2232583 · Cited by 4
“Since tau is considered to be among the primary drivers of early cognitive difficulties associated with AD (Brier et al., 2016), a focus on the link between serial position scores and pathological tau biomarkers is warranted.”
BackgroundAbbate, C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00308 · Cited by 4
“So it agrees with data suggesting that TAU pathology is a primary event in the development of AD (Brier et al., 2016; Shi et al., 2017).”
PET Amyloid and Tau Status Are Differently Affected by Patient Features
Tan, M., Initiative, A. D. N., Yang, Y., Wang, H.-F., Xu, W., Tan, C., Zuo, C., Dong, Q., Tan, L., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200124 · Cited by 4
Rueda, A., & Luis Fernando Enríquez, S. (2018) · Biosalud · doi:10.17151/biosa.2018.17.2.5 · Cited by 21
“ISSN 1657-9550 Los estudios de tau-PET muestran que las regiones de interés de relevancia en las que la tasa de captación estandarizadas (SUVR) exponen un efecto considerable en los niveles de esta proteína son la amígdala, la corteza occipital lateral, la corteza temporal inferior y el hipocampo, siendo mayor el patr…”
BackgroundAnderson, J. A. E., Schifani, C., Nazeri, A., Voineskos, A. N., & Initiative, A. D. N. (2021) · medRxiv · doi:10.1101/2021.03.26.21254351 · Cited by 4
Cushing, S. D., Moseley, S. C., Stimmell, A. C., Schatschneider, C. W., & Wilber, A. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.20.599921 · Cited by 3
“…given that tau often correlates with memory performance in both mouse models (Arendash et al., 2004; Santacruz et al., 2005; Huber et al., 2018; Stimmell et al., 2021) and human patients (Brier et al., 2016; Hanseeuw et al., 2019; Sperling et al., 2019) for review see (Giacobini and Gold, 2013).”
BackgroundZhang, C., Tai, Y., Kong, M., Jia, P., Ma, G., Ba, M., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322196 · Cited by 5
Nadh, A. G., Kunhikrishnan, M. J., Ravi, V., Ramakrishnan, K., Rehman, N., Adithya, K., Revikumar, A., Sudhakaran, P. R., & Raju, R. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00592-6 · Cited by 3
Xu, C., Xu, E., Xiao, Y., Yang, D., Wu, G., & Chen, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142887 · Cited by 5
Tau seeding activity in Alzheimer's disease: Characteristics, factors, and applications
Liu, Y., Chen, Y., Chen, Z., Wan, H., & Wu, C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251378772 · Cited by 4
“10,11 Depletion of tau has been shown to mitigate A β -induced neuroin fl ammation, mitochondrial dysfunction, and neurodegeneration.”
Spatial navigation as a digital marker for clinically differentiating cognitive impairment severity
Colombo, G., Minta, K., Taylor, W. R., Grübel, J., Chong, E. J. Y., Chong, J. R., Lim, M. J. H., Gonzales, P. N. G., Lai, M. K. P., Chen, C. P., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01484-y · Cited by 11
Weber, A. J., Ng, B., Greathouse, K. M., Bennett, D. A. A., Tasaki, S., Gaiteri, C., & Herskowitz, J. H. (2026) · Neuron · doi:10.1016/j.neuron.2026.03.001 · Cited by 5
Luikku, A. J., Nerg, O., Koivisto, A. M., Hänninen, T., Junkkari, A., Kemppainen, S., Juopperi, S.-P., Sinisalo, R., Pesola, A., Soininen, H., et al. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae083 · Cited by 5
Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models
Salem, S., Alpaugh, M., Saint‐Pierre, M., Borba, F. N., Cerquera‐Cleves, C., Lemieux, M., Ngonza-Nito, S. B., Koninck, P. D., Melki, R., & Cicchetti, F. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106696 · Cited by 3
Gogola, A., Lopresti, B. J., Minhas, D. S., López, O. L., Cohen, A. D., & Villemagne, V. L. (2025) · Geriatrics · doi:10.3390/geriatrics10010027 · Cited by 5
Stojanovic, M., Millar, P. R., McKay, N. S., Aschenbrenner, A. J., Balota, D. A., Hassenstab, J. J., Benzinger, T. L. S., Morris, J. C., & Ances, B. M. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251316801 · Cited by 3
Self-citationChen, Y., Wang, Z., Liu, X., Mao, Z., & Initiative, A. D. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05007-z · Cited by 6
Zhang, M., Hu, J., Zhang, Y., Meng, Z., Zhao, Y., Li, Y., Jin, W., Qian, X., Wang, L., Ye, G., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70332 · Cited by 2
Structural signature of sporadic Creutzfeldt–Jakob disease
Navid, J., Day, G. S., Strain, J. F., Perrin, R. J., Bucelli, R. C., Dincer, A., Wisch, J. K., Soleimani‐Meigooni, D. N., Morris, J. C., Benzinger, T. L. S., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13930 · Cited by 7
Self-citationBrain Amyloid in Sporadic Young Onset Alzheimer’s Disease
Panegyres, P. K., & Robins, P. D. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220110 · Cited by 3
Li, K., Luo, X., Zeng, Q., Liu, X., Li, J., Zhong, S., Zhang, X., Xu, X., Wang, S., Hong, H., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106354 · Cited by 5
“Considering the network-like distribution patterns of LATE-NC and AD pathology, network analysis may be a proper method to reflect the GM changes (Meneses et al., 2021; Brier et al., 2016).”
MethodTau positron emission tomography imaging in C9orf72 repeat expansion carriers
Ly, C. V., Koenig, L., Christensen, J. J., Gordon, B. A., Beaumont, H., Dahiya, S. M., Chen, Y.-H., Su, Y., Nelson, B., Jockel, J., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13940 · Cited by 5
Self-citationTau PET imaging evidence in patients with cognitive impairment: preparing for clinical use
Noirot, C., Mainta, I., Mendes, A., Andryszak, P., Visvaratnam, H., Unschuld, P. G., Frisoni, G. B., & Garibotto, V. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0297-4 · Cited by 4
Connectome-Mediated Prediction of Future Tau-PET Burden in Alzheimer’s Disease
Damasceno, P. F., Joie, R. L., Shcherbinin, S., Southekal, S. S., Kotari, V., Higgins, I. A., Collins, E. C., Rabinovici, G. D., Mintun, M. A., & Raj, A. (2022) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280065 · Cited by 4
Paric, A. (2019) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2019-13505 · Cited by 4
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.09.627436 · Cited by 3
Spatial Navigation as a Digital Marker for Clinically Differentiating Cognitive Impairment SeverityPreprint
Colombo, G., Minta, K., Taylor, W. R., Grübel, J., Chong, E. J. Y., Chong, J. R., Lim, M. J. H., Gonzales, P. N. G., Lai, M. K. P., Chen, C., et al. (2025) · medRxiv · doi:10.1101/2025.06.05.25329079 · Cited by 3
Hou, X., Zhang, W., Kang, K., Jin, Y., Ren, P., Wang, L., Li, Z., Li, Y., You, J., Zhang, B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71106 · Cited by 5
Dallari, C., Ladurner, G., Kendrisic, M., Caria, F. F., Manzl, C., Ponticelli, L., Perego, L., Goretti, F., Credi, C., Prokesch, M., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.5c04842 · Cited by 3
Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition
Ng, K. P., Initiative, A. D. N., Cheng, G. H. ‐., Yatawara, C., Rosa‐Neto, P., Gauthier, S. G., & Kandiah, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201425 · Cited by 2
Paulo, S. L., Ribeiro‐Rodrigues, L., Rodrigues, R. S., Mateus, J. M., Fonseca‐Gomes, J., Soares, R., Diógenes, M. J., Solá, S., Sebastião, A. M., Ribeiro, F. F., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201567 · Cited by 2
PET imaging in Down syndrome and Alzheimer's disease
Handen, B. L., & Christian, B. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00013-x · Cited by 5
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.